Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17586257 | 0.91 | ALDH1A1 (0.59) | ALDH1A1TSHRHSD17B10EPHX2HTT | |
| SCHEMBL21376713 | 0.90 | ALDH1A1 (0.56) | ALDH1A1TSHRHSD17B10EPHX2HTT | |
| SCHEMBL13173769 | 0.84 | ALDH1A1 (0.54) | ALDH1A1TSHRHSD17B10EPHX2HTT | |
| SCHEMBL15436470 | 0.84 | ALDH1A1 (0.54) | ALDH1A1TSHRHSD17B10EPHX2HTT | |
| SCHEMBL29602615 | 0.82 | ALDH1A1 (0.68) | ALDH1A1TSHRHSD17B10EPHX2HTT | |
| SCHEMBL2290939 | 0.81 | ALDH1A1 (1.00) | ALDH1A1TSHRHSD17B10EPHX2HTT | |
| SCHEMBL14644919 | 0.81 | ALDH1A1 (0.70) | ALDH1A1TSHRHSD17B10EPHX2HTT | |
| SCHEMBL11076664 | 0.81 | ALDH1A1 (0.70) | ALDH1A1TSHRHSD17B10EPHX2HTT | |
| SCHEMBL21376621 | 0.81 | ALDH1A1 (0.66) | ALDH1A1TSHRHSD17B10EPHX2HTT | |
| SCHEMBL8338683 | 0.80 | MEN1 (0.67) | ALDH1A1TSHRHSD17B10EPHX2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELI LILLY AND COMPANY (US) | 2020-07-07 | — | — | US | disclosed |
| WO-2019178248-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-20180265511-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2018-09-20 | — | — | US | disclosed |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
| US-20170049903-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2017-02-23 | — | — | US | disclosed |
| US-20150050233-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150031753-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20130197210-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130172549-A1 | Heteroaryl amide derivatives | H. LUNDBECK A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| US-8092833-B2 | Compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110256104-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110182864-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-07-28 | — | — | US | disclosed |
| US-7968123-B2 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-06-28 | — | — | US | disclosed |
| US-7807198-B2 | Compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100216763-A1 | Heteroaryl Amide Derivatives | H. LUNDBECK A/S (DK) | 2010-08-26 | — | — | US | disclosed |
| US-20100093747-A1 | METHOD OF INDUCING NEGATIVE CHEMOTAXIS | CELTAXSYS, INC. | 2010-04-15 | — | — | US | disclosed |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2009-06-04 | — | — | US | disclosed |
| US-20070128167-A1 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-06-07 | — | — | US | disclosed |
| US-7166302-B2 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELANE, CASP3, MMP8 | ALDH1A1 1104/4885TSHR 4745/4885HSD17B10 3677/4885 |
| US-20110256104-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | INTS6, EXOSC5, PCBP1 | ALDH1A1 3199/4885TSHR 4564/4885HSD17B10 2411/4885 |
| US-20100093747-A1 | METHOD OF INDUCING NEGATIVE CHEMOTAXIS | PMAIP1, CDC42, DCX | ALDH1A1 3761/4885TSHR 4209/4885HSD17B10 3018/4885 |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | ALDH1A1 968/4885TSHR 3225/4885HSD17B10 1209/4885 |
| US-20180265511-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | ALDH1A1 1104/4885TSHR 4745/4885HSD17B10 3677/4885 |
| US-20150031753-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | INTS6, EXOSC5, PCBP1 | ALDH1A1 3199/4885TSHR 4564/4885HSD17B10 2411/4885 |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | ALDH1A1 968/4885TSHR 3225/4885HSD17B10 1209/4885 |
| US-20110182864-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | EXOSC5, EXOSC9, INTS6 | ALDH1A1 2996/4885TSHR 4519/4885HSD17B10 2149/4885 |
| US-20070128167-A1 | Complexing agents for compositions containing inclusion complexes | INTS6, EXOSC5, PCBP1 | ALDH1A1 3199/4885TSHR 4564/4885HSD17B10 2411/4885 |
| US-20150050233-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | EXOSC5, EXOSC9, INTS6 | ALDH1A1 2996/4885TSHR 4519/4885HSD17B10 2149/4885 |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | ALDH1A1 1104/4885TSHR 4745/4885HSD17B10 3677/4885 |
| US-20100216763-A1 | Heteroaryl Amide Derivatives | HCAR2, PIGS, GPR52 | ALDH1A1 1276/4885TSHR 62/4885HSD17B10 1049/4885 |
| US-20170049903-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | INTS6, EXOSC5, PCBP1 | ALDH1A1 3199/4885TSHR 4564/4885HSD17B10 2411/4885 |
| US-20130172549-A1 | Heteroaryl amide derivatives | HCAR2, PIGS, GPR52 | ALDH1A1 1276/4885TSHR 62/4885HSD17B10 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.